158 related articles for article (PubMed ID: 1536948)
1. High molecular weight kininogen binds to platelets by its heavy and light chains and when bound has altered susceptibility to kallikrein cleavage.
Meloni FJ; Gustafson EJ; Schmaier AH
Blood; 1992 Mar; 79(5):1233-44. PubMed ID: 1536948
[TBL] [Abstract][Full Text] [Related]
2. Low molecular weight kininogen binds to platelets to modulate thrombin-induced platelet activation.
Meloni FJ; Schmaier AH
J Biol Chem; 1991 Apr; 266(11):6786-94. PubMed ID: 2016293
[TBL] [Abstract][Full Text] [Related]
3. Bradykinin regulates the expression of kininogen binding sites on endothelial cells.
Zini JM; Schmaier AH; Cines DB
Blood; 1993 Jun; 81(11):2936-46. PubMed ID: 8388750
[TBL] [Abstract][Full Text] [Related]
4. Human high molecular weight kininogen binds to human umbilical vein endothelial cells via its heavy and light chains.
Reddigari SR; Kuna P; Miragliotta G; Shibayama Y; Nishikawa K; Kaplan AP
Blood; 1993 Mar; 81(5):1306-11. PubMed ID: 8443392
[TBL] [Abstract][Full Text] [Related]
5. Domain 3 of kininogens contains a cell-binding site and a site that modifies thrombin activation of platelets.
Jiang YP; Muller-Esterl W; Schmaier AH
J Biol Chem; 1992 Feb; 267(6):3712-7. PubMed ID: 1740422
[TBL] [Abstract][Full Text] [Related]
6. The carboxyl terminus of bradykinin and amino terminus of the light chain of kininogens comprise an endothelial cell binding domain.
Hasan AA; Cines DB; Zhang J; Schmaier AH
J Biol Chem; 1994 Dec; 269(50):31822-30. PubMed ID: 7989355
[TBL] [Abstract][Full Text] [Related]
7. High molecular weight kininogen binds to Mac-1 on neutrophils by its heavy chain (domain 3) and its light chain (domain 5).
Wachtfogel YT; DeLa Cadena RA; Kunapuli SP; Rick L; Miller M; Schultze RL; Altieri DC; Edgington TS; Colman RW
J Biol Chem; 1994 Jul; 269(30):19307-12. PubMed ID: 8034694
[TBL] [Abstract][Full Text] [Related]
8. Characterization of cell binding and thrombin inhibitory regions on kininogens' heavy chain.
Jiang YP; Schmaier AH
Agents Actions Suppl; 1992; 38 ( Pt 1)():233-40. PubMed ID: 1466275
[TBL] [Abstract][Full Text] [Related]
9. High-molecular-mass and low-molecular-mass kininogens block plasmin-induced platelet aggregation by forming a complex with kringle 5 of plasminogen/plasmin.
Selim TE; Ghoneim HR; Uknis AB; Colman RW; DeLa Cadena RA
Eur J Biochem; 1997 Dec; 250(2):532-8. PubMed ID: 9428707
[TBL] [Abstract][Full Text] [Related]
10. Expression of thrombospondin 1 on the surface of activated platelets mediates their interaction with the heavy chains of human kininogens through Lys 244-Pro 254.
DeLa Cadena RA; Kunapuli SP; Walz DA; Colman RW
Thromb Haemost; 1998 Jan; 79(1):186-94. PubMed ID: 9459346
[TBL] [Abstract][Full Text] [Related]
11. Surface-induced alterations in the kinetic pathway for cleavage of human high molecular weight kininogen by plasma kallikrein.
Tayeh MA; Olson ST; Shore JD
J Biol Chem; 1994 Jun; 269(23):16318-25. PubMed ID: 8206938
[TBL] [Abstract][Full Text] [Related]
12. Insights on monoclonal antibodies to kininogens' heavy chain which influence kininogens' binding to platelets.
Jiang Y; Nawarawong W; Meloni FJ; Schmaier AH
Thromb Haemost; 1992 Aug; 68(2):143-8. PubMed ID: 1412158
[TBL] [Abstract][Full Text] [Related]
13. High molecular weight kininogen inhibits thrombin-induced platelet aggregation and cleavage of aggregin by inhibiting binding of thrombin to platelets.
Puri RN; Zhou F; Hu CJ; Colman RF; Colman RW
Blood; 1991 Feb; 77(3):500-7. PubMed ID: 1846761
[TBL] [Abstract][Full Text] [Related]
14. High molecular weight kininogen peptides inhibit the formation of kallikrein on endothelial cell surfaces and subsequent urokinase-dependent plasmin formation.
Lin Y; Harris RB; Yan W; McCrae KR; Zhang H; Colman RW
Blood; 1997 Jul; 90(2):690-7. PubMed ID: 9226169
[TBL] [Abstract][Full Text] [Related]
15. The kinin released from high molecular weight-kininogen is responsible for inflammatory exudation in rats: detection of kinin-free-kininogen in the exudate by immunoblot analysis.
Fujie H; Hayashi I; Oh-ishi S
Life Sci; 1993; 53(22):1691-701. PubMed ID: 8231650
[TBL] [Abstract][Full Text] [Related]
16. Kinetics of inhibition of platelet calpain II by human kininogens.
Bradford HN; Schmaier AH; Colman RW
Biochem J; 1990 Aug; 270(1):83-90. PubMed ID: 2396995
[TBL] [Abstract][Full Text] [Related]
17. Platelet thrombospondin interactions with human high and low molecular weight kininogens.
DeLa Cadena RA; Wyshock EG; Kunapuli SP; Schultze RL; Miller M; Walz DA; Colman RW
Thromb Haemost; 1994 Jul; 72(1):125-31. PubMed ID: 7974360
[TBL] [Abstract][Full Text] [Related]
18. The sequence HGLGHGHEQQHGLGHGH in the light chain of high molecular weight kininogen serves as a primary structural feature for zinc-dependent binding to an anionic surface.
DeLa Cadena RA; Colman RW
Protein Sci; 1992 Jan; 1(1):151-60. PubMed ID: 1304876
[TBL] [Abstract][Full Text] [Related]
19. Modulation of thrombin-induced platelet aggregation by inhibition of calpain by a synthetic peptide derived from the thiol-protease inhibitory sequence of kininogens and S-(3-nitro-2-pyridinesulfenyl)-cysteine.
Puri RN; Matsueda R; Umeyama H; Bradford HN; Colman RW
Eur J Biochem; 1993 May; 214(1):233-41. PubMed ID: 8389701
[TBL] [Abstract][Full Text] [Related]
20. High molecular weight kininogen binds to unstimulated platelets.
Gustafson EJ; Schutsky D; Knight LC; Schmaier AH
J Clin Invest; 1986 Jul; 78(1):310-8. PubMed ID: 3722381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
